The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Horwitz, E. M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Deans, R. J., Krause, D. S., & Keating, A. (2005) · Cytotherapy · doi:10.1080/14653240500319234 · Cited by 2,073
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.-U., Dlugosz, A., Szakos, A., Hassan, Z., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000214462.63943.14 · Cited by 1,142
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018
DiGirolamo, C. M., Stokes, D., Colter, D., Phinney, D. G., Class, R., & Prockop, D. J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01715.x · Cited by 879
Cited by
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
“sponsored phase 3 trial of MSC therapy for GVHD following hematopoietic stem cell transplantation did not meet its proposed endpoints across all ages but showed life-saving benefit in the pediatric patients.(127,128) The results did lead to the first approvals for a culture-expanded MSC product for cell therapy agains…”
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
“Industrialsponsored manufactured allogeneic MSC cells allow for manufacture of up to 1 million doses per donor for mass deployment, whereas a mix of autologous or allogeneic MSCs are used by academic centers, which typically manufacture no more than 10 doses per donor(Galipeau, 2013).”
BackgroundSelf-citationClinical Trials with Mesenchymal Stem Cells: An Update
Squillaro, T., Peluso, G., & Galderisi, U. (2016) · Cell Transplantation · doi:10.3727/096368915x689622 · Cited by 1,395
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Three-Dimensional Cell Cultures in Drug Discovery and Development
Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849
“In addition, clinical observations show that the beneficial effects of stem cell–based therapeutics seen in initial small-scale clinical studies are often not validated by large, randomized clinical trials.(123,124) In fact, MSCs often decrease their replicative ability, colonyforming efficiency, and differentiation c…”
BackgroundShattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement
Ullah, M., Liu, D. D., & Thakor, A. S. (2019) · iScience · doi:10.1016/j.isci.2019.05.004 · Cited by 549
Spheroid Culture of Mesenchymal Stem Cells
Cesarz, Z., & Tamama, K. (2016) · Stem Cells International · doi:10.1155/2016/9176357 · Cited by 475
MSC-Based Product Characterization for Clinical Trials: An FDA Perspective
Mendicino, M., Bailey, A. M., Wonnacott, K., Puri, R. K., & Bauer, S. R. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.013 · Cited by 497
Krampera, M., Galipeau, J., Shi, Y., Tarte, K., & Sensebe, L. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.010 · Cited by 464
Self-citationSart, S., Tsai, A.-C., Li, Y., & Ma, T. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0537 · Cited by 382
Moll, G., Alm, J. J., Davies, L. C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., Hamad, O. A., Hinsch, R., Ignatowicz, L., Locke, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1729 · Cited by 381
Marquez-Curtis, L. A., Janowska-Wieczorek, A., McGann, L. E., & Elliott, J. A. W. (2015) · Cryobiology · doi:10.1016/j.cryobiol.2015.07.003 · Cited by 346
Manufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Wang, L.-T., Ting, C.-H., Yen, M.-L., Liu, K.-J., Sytwu, H.-K., Wu, K. K., & Yen, B. L. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0289-5 · Cited by 341
Forbes, G. M., Sturm, M. J., Leong, R. W., Sparrow, M. P., Segarajasingam, D., Cummins, A. G., Phillips, M., & Herrmann, R. P. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.06.021 · Cited by 333
Enhancing the Migration Ability of Mesenchymal Stromal Cells by Targeting the SDF-1/CXCR4 Axis
Marquez-Curtis, L. A., & Janowska-Wieczorek, A. (2013) · BioMed Research International · doi:10.1155/2013/561098 · Cited by 287
Bloor, A. J. C., Patel, A., Griffin, J. E., Gilleece, M. H., Radia, R., Yeung, D. T., Drier, D., Larson, L. S., Uenishi, G. I., Hei, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1050-x · Cited by 284
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
“Although host factors, source, and functionality of MSCs may contribute to inconsistent outcomes of clinical trials, a better understanding of cellular immunology of MSCs would help to optimize and possibly enhance the pharmaceutical utility of such cells (13, 16).”
BackgroundSelf-citationCurrent status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles
Park, K.-S., Bandeira, E., Shelke, G. V., Lässer, C., & Lötvall, J. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1398-3 · Cited by 256
Chinnadurai, R., Garcia, M. A., Sakurai, Y., Lam, W. A., Kirk, A. D., Galipeau, J., & Copland, I. B. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.05.003 · Cited by 139
“However, discrepancies in the therapeutic effectiveness of these cells as determined in phase II/III trials have called into question their therapeutic utility (Galipeau, 2013).”
BackgroundSelf-citationThe issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
“Unfortunately, such expansion can signi fi cantly alter MSC characteristics and has been proposed as a possible cause for poor performance in certain clinical trials (Galipeau, 2013; Hoch and Leach, 2014).”
BackgroundKuci, Z., Bonig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., kifi, M., Michel, K., Eising, B., Lucchini, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140368 · Cited by 118
Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period
Antebi, B., Asher, A. M., Rodriguez, L. A., Moore, R. K., Mohammadipoor, A., & Cancio, L. C. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2038-5 · Cited by 83
Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use
Bieback, K., Kuçi, S., & Schäfer, R. (2019) · Transfusion · doi:10.1111/trf.15252 · Cited by 24
Mebarki, M., Moine-Picard, C., Enjaume-Rauch, R., Laurent-Puig, A., Suissa, A., Feyants, V., Larghero, J., & Cras, A. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04361-y · Cited by 16
Mamo, T., Cox, C. A., Demorest, C., Fontaine, M. J., Hubel, A., Kelley, L., Khan, A., Marks, D. C., Pati, S., Reems, J.-A., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.07.001 · Cited by 16
Metadata
- Authors
- Galipeau, J.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 15
- Issue
- 1
- Pages
- 2-8
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2058473775
- Cited by
- 448
- References
- 61
- FWCI
- 32.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.